Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1880-1892

  Cummings, Maxwell D ^a,b   Lin, Tse I ^a,c   Hu, Lili ^a   Tahri, Abdellah ^a   McGowan, David ^a   Amssoms, Katie ^a   Last, Stefaan ^a   Devogelaere, Benoit ^a,d   Rouan, Marie Claude ^a   Vijgen, Leen ^a   Berke, Jan Martin ^a   Dehertogh, Pascale ^a   Fransen, Els ^a   Cleiren, Erna ^a   Van Der Helm, Liesbet ^a   Fanning, Gregory ^a   Nyanguile, Origène ^a,e   Simmen, Kenny ^a   Van Remoortere, Pieter ^a   Raboisson, Pierre ^a,b   Vendeville, Sandrine ^a   more..

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Roche China Ltd   (China)

^d Cartagenia   (Belgium)

^e UNIVERSITY OF APPLIED SCIENCES WESTERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MACROCYCLIC COMPOUND; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; RITONAVIR; SIMEPREVIR; TMC 647055; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOOSE FECES; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896284007     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401396p     Document Type: Article

References (42)

1. El-Serag, H. B. Hepatocellular carcinoma N. Engl. J. Med. 2011, 365, 1118-1127
2. Ghany, M. G.; Strader, D. B.; Thomas, D. L.; Seeff, L. B. American Association for the Study of Liver, D. Diagnosis, management, and treatment of hepatitis C: An update Hepatology 2009, 49, 1335-1374
3. The Global Burden of Hepatitis, C. W. G. Global Burden of Disease (GBD) for Hepatitis C. J. Clin. Pharmacol. 2004, 44, 20-29.
4. Bacon, B. R.; Gordon, S. C.; Lawitz, E.; Marcellin, P.; Vierling, J. M.; Zeuzem, S.; Poordad, F.; Goodman, Z. D.; Sings, H. L.; Boparai, N.; Burroughs, M.; Brass, C. A.; Albrecht, J. K.; Esteban, R. Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 2011, 364, 1207-1217
5. Poordad, F.; McCone, J.; Bacon, B. R.; Bruno, S.; Manns, M. P.; Sulkowski, M. S.; Jacobson, I. M.; Reddy, K. R.; Goodman, Z. D.; Boparai, N.; DiNubile, M. J.; Sniukiene, V.; Brass, C. A.; Albrecht, J. K.; Bronowicki, J.-P. Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 2011, 364, 1195-1206
6. Jacobson, I. M.; McHutchison, J. G.; Dusheiko, G.; Di Bisceglie, A. M.; Reddy, K. R.; Bzowej, N. H.; Marcellin, P.; Muir, A. J.; Ferenci, P.; Flisiak, R.; George, J.; Rizzetto, M.; Shouval, D.; Sola, R.; Terg, R. A.; Yoshida, E. M.; Adda, N.; Bengtsson, L.; Sankoh, A. J.; Kieffer, T. L.; George, S.; Kauffman, R. S.; Zeuzem, S. Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 2011, 364, 2405-2416
7. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G. R.; Horban, A.; Ferenci, P.; Nevens, F.; Mullhaupt, B.; Pockros, P.; Terg, R.; Shouval, D.; van Hoek, B.; Weiland, O.; Van Heeswijk, R.; De Meyer, S.; Luo, D.; Boogaerts, G.; Polo, R.; Picchio, G.; Beumont, M. Telaprevir for retreatment of HCV infection N. Engl. J. Med. 2011, 364, 2417-2428
8. Behrens, S. E.; Tomei, L.; De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus EMBO J. 1996, 15, 12-22
9. Lohmann, V.; Korner, F.; Herian, U.; Bartenschlager, R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity J. Virol. 1997, 71, 8416-8428
10. Carroll, S. S.; Olsen, D. B. Nucleoside analog inhibitors of hepatitis C virus replication Infect. Disord.: Drug Targets 2006, 6, 17-29
11. Jonckers, T. H. M.; Lin, T.-I.; Buyck, C.; Lachau-Durand, S.; Vandyck, K.; Van Hoof, S.; Vandekerckhove, L. A. M.; Hu, L.; Berke, J. M.; Vijgen, L.; Dillen, L. L. A.; Cummings, M. D.; de Kock, H.; Nilsson, M.; Sund, C.; Rydegard, C.; Samuelsson, B.; Rosenquist, A.; Fanning, G.; Van Emelen, K.; Simmen, K.; Raboisson, P. 2′-Deoxy-2′-spirocyclopropylcytidine revisited: A new and selective inhibitor of the hepatitis C virus NS5B polymerase J. Med. Chem. 2010, 53, 8150-8160
12. Beaulieu, P. L. Non-nucleoside inhibitors of the HCV NS5B polymerase: Progress in the discovery and development of novel agents for the treatment of HCV infections Curr. Opin. Invest. Drugs 2007, 8, 614-634
13. Koch, U.; Narjes, F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase Infect. Disord.: Drug Targets 2006, 6, 31-41
14. Tramontano, E. The exploding field of the HCV polymerase non-nucleoside inhibitors: Summary of first generation compounds Mini-Rev. Med. Chem. 2008, 8, 1298-1310
15. Di Marco, S.; Volpari, C.; Tomei, L.; Altamura, S.; Harper, S.; Narjes, F.; Koch, U.; Rowley, M.; De Francesco, R.; Migliaccio, G.; Carfi, A. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site J. Biol. Chem. 2005, 280, 29765-29770
16. Kukolj, G.; McGibbon, G. A.; McKercher, G.; Marquis, M.; Lefebvre, S.; Thauvette, L.; Gauthier, J.; Goulet, S.; Poupart, M.-A.; Beaulieu, P. L. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase J. Biol. Chem. 2005, 280, 39260-39267
17. Tomei, L.; Altamura, S.; Bartholomew, L.; Biroccio, A.; Ceccacci, A.; Pacini, L.; Narjes, F.; Gennari, N.; Bisbocci, M.; Incitti, I.; Orsatti, L.; Harper, S.; Stansfield, I.; Rowley, M.; De Francesco, R.; Migliaccio, G. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase J. Virol. 2003, 77, 13225-13231
18. Beaulieu, P. L.; Gillard, J.; Bykowski, D.; Brochu, C.; Dansereau, N.; Duceppe, J. S.; Hache, B.; Jakalian, A.; Lagace, L.; LaPlante, S.; McKercher, G.; Moreau, E.; Perreault, S.; Stammers, T.; Thauvette, L.; Warrington, J.; Kukolj, G. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds Bioorg. Med. Chem. Lett. 2006, 16, 4987-4993
19. Beaulieu, P. L.; Bos, M.; Cordingley, M. G.; Chabot, C.; Fazal, G.; Garneau, M.; Gillard, J. R.; Jolicoeur, E.; LaPlante, S.; McKercher, G.; Poirier, M.; Poupart, M. A.; Tsantrizos, Y. S.; Duan, J.; Kukolj, G. Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV) J. Med. Chem. 2012, 55, 7650-7666
20. Narjes, F.; Crescenzi, B.; Ferrara, M.; Habermann, J.; Colarusso, S.; Ferreira, M. d. R. R.; Stansfield, I.; Mackay, A. C.; Conte, I.; Ercolani, C.; Zaramella, S.; Palumbi, M.-C.; Meuleman, P.; Leroux-Roels, G.; Giuliano, C.; Fiore, F.; Di Marco, S.; Baiocco, P.; Koch, U.; Migliaccio, G.; Altamura, S.; Laufer, R.; De Francesco, R.; Rowley, M. Discovery of (7 R)-14-cyclohexyl-7-{[2- (dimethylamino)ethyl](methyl)amino}-7,8-dihydro-6 H -indolo[1,2- e ][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase J. Med. Chem. 2011, 54, 289-301
21. Giuliano, C.; Fiore, F.; Di Marco, A.; Padron Velazquez, J.; Bishop, A.; Bonelli, F.; Gonzalez-Paz, O.; Marcucci, I.; Harper, S.; Narjes, F.; Pacini, B.; Monteagudo, E.; Migliaccio, G.; Rowley, M.; Laufer, R. Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase Xenobiotica 2005, 35, 1035-1054
22. Bailey, M. J.; Dickinson, R. G. Acyl glucuronide reactivity in perspective: Biological consequences Chem.-Biol. Interact. 2003, 145, 117-137
23. Castillo, M.; Smith, P. C. Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin Drug Metab. Dispos. 1995, 23, 566-572
24. Skonberg, C.; Olsen, J.; Madsen, K. G.; Hansen, S. H.; Grillo, M. P. Metabolic activation of carboxylic acids Expert Opin. Drug Metab. Toxicol. 2008, 4, 425-438
25. Zhao, Y. H.; Abraham, M. H.; Le, J.; Hersey, A.; Luscombe, C. N.; Beck, G.; Sherborne, B.; Cooper, I. Rate-limited steps of human oral absorption and QSAR studies Pharm. Res. 2002, 19, 1446-1457
26. Ikegashira, K.; Oka, T.; Hirashima, S.; Noji, S.; Yamanaka, H.; Hara, Y.; Adachi, T.; Tsuruha, J.-I.; Doi, S.; Hase, Y.; Noguchi, T.; Ando, I.; Ogura, N.; Ikeda, S.; Hashimoto, H. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors J. Med. Chem. 2006, 49, 6950-6953
27. McGowan, D.; Vendeville, S.; Lin, T. I.; Tahri, A.; Hu, L.; Cummings, M. D.; Amssoms, K.; Berke, J. M.; Canard, M.; Cleiren, E.; Dehertogh, P.; Last, S.; Fransen, E.; Van Der Helm, E.; Van den Steen, I.; Vijgen, L.; Rouan, M. C.; Fanning, G.; Nyanguile, O.; Van Emelen, K.; Simmen, K.; Raboisson, P. Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series Bioorg. Med. Chem. Lett. 2012, 22, 4431-4436
28. Vendeville, S.; Lin, T. I.; Hu, L.; Tahri, A.; McGowan, D.; Cummings, M. D.; Amssoms, K.; Canard, M.; Last, S.; Van den Steen, I.; Devogelaere, B.; Rouan, M. C.; Vijgen, L.; Berke, J. M.; Dehertogh, P.; Fransen, E.; Cleiren, E.; van der Helm, L.; Fanning, G.; Van Emelen, K.; Nyanguile, O.; Simmen, K.; Raboisson, P. Finger-loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055 Bioorg. Med. Chem. Lett. 2012, 22, 4437-4443
29. Lin, T.-I.; Lenz, O.; Fanning, G.; Verbinnen, T.; Delouvroy, F.; Scholliers, A.; Vermeiren, K.; Rosenquist, A.; Edlund, M.; Samuelsson, B.; Vrang, L.; de Kock, H.; Wigerinck, P.; Raboisson, P.; Simmen, K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 2009, 53, 1377-1385
30. Raboisson, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T.-I.; Roue, N.; Ivanov, V.; Wahling, H.; Wickstrom, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350 Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858
31. Cummings, M. D.; Lin, T. I.; Hu, L.; Tahri, A.; McGowan, D.; Amssoms, K.; Last, S.; Devogelaere, B.; Rouan, M. C.; Vijgen, L.; Berke, J. M.; Dehertogh, P.; Fransen, E.; Cleiren, E.; van der Helm, L.; Fanning, G.; Van Emelen, K.; Nyanguile, O.; Simmen, K.; Raboisson, P.; Vendeville, S. Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties Angew. Chem., Int. Ed. 2012, 51, 4637-4640
32. Devogelaere, B.; Berke, J. M.; Vijgen, L.; Dehertogh, P.; Fransen, E.; Cleiren, E.; van der Helm, L.; Nyanguile, O.; Tahri, A.; Amssoms, K.; Lenz, O.; Cummings, M. D.; Clayton, R. F.; Vendeville, S.; Raboisson, P.; Simmen, K. A.; Fanning, G. C.; Lin, T.-I. TMC647055, a potent non-nucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage Antimicrob. Agents Chemother. 2012, 56, 4676-4684
33. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinàs-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 426, 186-189
34. Liverton, N. J.; Holloway, M. K.; McCauley, J. A.; Rudd, M. T.; Butcher, J. W.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K. F.; Mao, S.-S.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Stahlhut, M.; Wan, B.-L.; Olsen, D. B.; Vacca, J. P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease J. Am. Chem. Soc. 2008, 130, 4607-4609
35. Biswal, B. K.; Cherney, M. M.; Wang, M.; Chan, L.; Yannopoulos, C. G.; Bilimoria, D.; Nicolas, O.; Bedard, J.; James, M. N. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors J. Biol. Chem. 2005, 280, 18202-18210
36. Beaulieu, P. L.; Coulombe, R.; Gillard, J.; Brochu, C.; Duan, J.; Garneau, M.; Jolicoeur, E.; Kuhn, P.; Poupart, M.-A.; Rancourt, J.; Stammers, T. A.; Thavonekham, B.; Kukolj, G. Allosteric N -acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase- Acylsulfonamides and acyl sulfamides as carboxylic acid replacements Can. J. Chem. 2013, 91, 66-81
37. Zheng, X.; Hudyma, T. W.; Martin, S. W.; Bergstrom, C.; Ding, M.; He, F.; Romine, J.; Poss, M. A.; Kadow, J. F.; Chang, C. H.; Wan, J.; Witmer, M. R.; Morin, P.; Camac, D. M.; Sheriff, S.; Beno, B. R.; Rigat, K. L.; Wang, Y. K.; Fridell, R.; Lemm, J.; Qiu, D.; Liu, M.; Voss, S.; Pelosi, L.; Roberts, S. B.; Gao, M.; Knipe, J.; Gentles, R. G. Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus Bioorg. Med. Chem. Lett. 2011, 21, 2925-2929
38. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2006, 5, 730-739
39. Pauwels, F.; Mostmans, W.; Quirynen, L. M.; van der Helm, L.; Boutton, C. W.; Rueff, A. S.; Cleiren, E.; Raboisson, P.; Surleraux, D.; Nyanguile, O.; Simmen, K. A. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors J. Virol. 2007, 81, 6909-6919
40. Rydberg, E. H.; Cellucci, A.; Bartholomew, L.; Mattu, M.; Barbato, G.; Ludmerer, S. W.; Graham, D. J.; Altamura, S.; Paonessa, G.; De Francesco, R.; Migliaccio, G.; Carfi, A. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors J. Mol. Biol. 2009, 390, 1048-1059
41. Lenz, O.; Verbinnen, T.; Lin, T.-I.; Vijgen, L.; Cummings, M. D.; Lindberg, J.; Berke, J. M.; Dehertogh, P.; Fransen, E.; Scholliers, A.; Vermeiren, K.; Ivens, T.; Raboisson, P.; Edlund, M.; Storm, S.; Vrang, L.; de Kock, H.; Fanning, G. C.; Simmen, K. A. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob. Agents Chemother. 2010, 54, 1878-1887
42. Bourgeois, S.; Reesink, H. W.; Leempoels, J.; Vijgen, L.; Rouan, M.-C.; Marien, K.; Remoortere, P. V.; Fanning, G.; Picchio, G.; Simmen, K.; Verloes, R. Combination Therapy of TMC647055 with Simeprevir (TMC435) in Genotype 1 HCV Patients. EASL, The International Liver Conference, Amsterdam, 2013.